The redemption of α-GPC benefits extended until March 15

The MOHW orders 129 pharmaceutical companies to negotiate or contract 227 items

The negotiation rate was 0% until February 10, the date of the end of the first negotiation

The contract for reimbursement of benefits related to α-GPC, a brain function improvement drug, was extended until March 15th.

 

The MOHW ordered The NHIS to extend the deadline for negotiations on the Choline alfoscerate formulation on the 10th.

 

February 10, which ordered an extension of the negotiation period, marks the end of the first negotiations for the MOHW to end negotiations and contracts for 129 pharmaceutical companies and 227 items of α-GPC(Choline alfoscerate).

 

On December 14, 2020, the MOHW ordered the termination of the contract for reimbursement of benefits for Choline alfoscerate by February 10 in accordance with the Rules on the Standards of National Health Insurance Medical Benefits.

 

A total of 56 pharmaceutical companies, including 28 pharmaceutical companies such as Chong Kun Dang and 28 pharmaceutical companies including Daewoong, among the 129 pharmaceutical companies to be negotiated, have suspended executions and administrative litigation regarding the cancellation of negotiation orders and notifications against the Minister of Health and Welfare and the Chairman of the NHIS.

 

During the negotiation period, the Seoul Administrative Court dismissed pharmaceutical companies' applications for suspension of execution on January 27 and 29, but disapproved with the results as pharmaceutical companies filed appeals.

 

Dissatisfaction with the results of the court had an impact on the negotiation process.

 

This is because there was no pharmaceutical company that agreed to the NHIS' redemption contract until February 10, when the negotiations ended.

 

The MOHW decided to extend the redemption negotiation order for one month.

 

According to Article 2-2, Paragraph 2 of the Drug Price Negotiation Guidelines, in spite of '1 (60 days from the day after the day after the Minister of Welfare ordered the negotiation), each subparagraph (if the Minister of Welfare ordered the negotiation by setting a separate negotiation period), If the Minister of Health and Welfare has ordered a temporary suspension of negotiations or postponement of the negotiation deadline pursuant to Article 11, Paragraph 2 of the Standards for Medical Benefits), it shall be up to a period or time limit separately determined in accordance with each subparagraph.

 

The negotiation period was specified.

 

In the case of Choline alfoscerate, when the NHIS Chairman requests the Minister of Health and Welfare for reasons such as delay in accordance with Article 11-2, Paragraph 7 of the Rules, the deadline may be delayed or temporarily suspended within 60 days.

 

The NHIS will conduct negotiations again for each pharmaceutical company during the extended negotiation period for an additional month.

 

In the event of a clinical trial failure, pharmaceutical companies must agree to return or break down the entire health insurance prescription amount from the date of submission of the clinical protocol to the MFDS to the date of deletion to the NHIS.

 

The reimbursement for the current health insurance prescription amount refers to the total medical care benefit expenses excluding the patient's copayment.

 

However, there is a possibility that it will change during the negotiation process, such as a lawsuit.